Two biotechs press for­ward with IPOs in a bid to stir mar­ket from hi­ber­na­tion

A bruis­ing bear mar­ket has left the biotech sec­tor bereft of IPOs in re­cent months, but in a small sign of mar­ket ac­tiv­i­ty, two com­pa­nies filed to go pub­lic over the last two days.

On Wednes­day, Hill­e­Vax, a norovirus vac­cine de­vel­op­er spunout from Take­da by late biotech leg­end Tachi Ya­ma­da, sub­mit­ted its SEC pa­per­work, pen­cil­ing in an ini­tial $100 mil­lion es­ti­mate. The fil­ing came a day af­ter Be­lite Bio sub­mit­ted its own F-1 — a reg­is­tra­tion state­ment for for­eign com­pa­nies — seek­ing $46 mil­lion in its es­ti­mate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER